PERCHLORACAP
LOE Approachingpotassium perchlorate
NDAORALCAPSULE
Approved
Nov 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Perchloracap is an oral potassium perchlorate capsule approved in 1974 for management of thyroid conditions. The mechanism of action involves inhibition of iodine uptake by the thyroid gland, reducing thyroid hormone synthesis. It is indicated for patients requiring thyroid suppression or management of hyperthyroidism-related conditions.
LOE Approaching
Product faces imminent loss of exclusivity with moderate competitive pressure; commercial teams are likely focused on transition strategy and generic preparation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Perchloracap offers limited career growth given its LOE-approaching lifecycle and minimal linked job activity. Roles available are primarily defensive and focused on managing market transition rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.